Evaluation of Exenatide in Patients With Diabetic Neuropathy

NCT00855439 · Completed

Last updated 2026-05-28

This clinical trial tested the medication exenatide in adults with type 2 diabetes who also have nerve damage in their hands or feet.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 46 people

Who can join Ages 18–70 · all sexes

Timeline Started 2008-06 · est. completion 2014-05

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT00855439 ↗

Description as written by the study sponsor.

This study will look at whether or not the medication exenatide improves signs and symptoms of diabetic peripheral neuropathy in people with type 2 diabetes and mild to moderate diabetic peripheral neuropathy.

Treatments tested

Exenatide also known as Byetta Drug

Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels
Glargine also known as Lantus Drug

Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control

Main thing measured	Confirmed Clinical Neuropathy (CCN)
Sponsor	University of Michigan
Conditions studied	Type 2 Diabetes Mellitus, Diabetic Peripheral Neuropathy
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00855439 ↗